



Confirmation No.: 3532
Due Date: April 29, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: David M. Koelle et al. Examiner: to be assigned
Serial No.: 10/623,429 Group Art Unit: 1645
Filed: July 18, 2003 Docket: G&C 30967.11-US-U1
Title: RAPID, EFFICIENT PURIFICATION OF HSV-SPECIFIC T-LYMPHOCYTES AND HSV
ANTIGENS IDENTIFIED VIA SAME

CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on April 6, 2004.

By: 

Name: Karen S. Canady

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

We are transmitting herewith the attached:

- ☒ Transmittal sheet, in duplicate, containing a Certificate of Mailing under 37 CFR 1.8.
- ☒ Supplemental Information Disclosure Statement and Form PTO-1449.
- ☒ Cited Reference(s).
- ☒ Copy of International Search Report for International Application No. PCT/US03/22560.
- ☒ Return postcard.

Please consider this a **PETITION FOR EXTENSION OF TIME** for a sufficient number of months to enter these papers, if appropriate.

Please charge all fees to Deposit Account No. 50-0494 of Gates & Cooper LLP. A duplicate of this paper is enclosed.

Customer Number 22462


GATES & COOPER LLP

Howard Hughes Center
6701 Center Drive West, Suite 1050
Los Angeles, CA 90045
(310) 641-8797

By: 

Name: Karen S. Canady
Reg. No.: 39,927
KSC/dr

(PTO TRANSMITTAL - GENERAL)




IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: David M. Koelle et al. Examiner: to be assigned
Serial No.: 10/623,429 Group Art Unit: 1645
Filed: July 18, 2003 Docket: G&C 30967.11-US-U1
Title: RAPID, EFFICIENT PURIFICATION OF HSV-SPECIFIC T-LYMPHOCYTES
AND HSV ANTIGENS IDENTIFIED VIA SAME

CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on April 6, 2004.

By: 
Name: Karen S. Canady

SUPPLEMENTAL INFORMATION DISCLOSURE

STATEMENT(37 C.F.R. §1.97(b)/(c))

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 2213-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner. Included are references that were recently cited in an International Search Report.

This statement should be considered because it is submitted prior to a first Office Action on the merits, and also less than three months after the mailing date of a Communication from a foreign patent office in which the aforementioned items of information were cited, but before the mailing date of either a final action under 37 C.F.R. § 1.113, or a Notice of Allowance under 37 C.F.R. § 1.311. No fee is due as this statement is submitted as certified below under 37 C.F.R. §1.97(e)(1) or (2) by the undersigned.

Certification Under 37 C.F.R. §1.97(e)

In accordance with 37 C.F.R. §1.97(c) or §1.97(d), the undersigned hereby certifies that this statement is submitted wherein each item of information listed on the enclosed Form 1449 was first cited in a communication from a foreign patent office in a counterpart foreign application within three months of filing this statement (certification under 37 C.F.R. §1.97(e)(1)).

In accordance with 37 C.F.R. §1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art". Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please direct any response or inquiry to the below-signed attorney at (310) 641-8797.

Respectfully submitted,

GATES & COOPER LLP
Attorneys for Applicant(s)

Howard Hughes Center
6701 Center Drive West, Suite 1050
Los Angeles, California 90045
(310) 641-8797

Date: April 6, 2004

KSC/dr

By: 

Karen S. Canady
Reg. No.: 39,927

Form 1449*	Docket Number: G&C 30967.11-US-U1	Application Number: 10/623,429
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	Applicant: David M. Koelle et al.	
	Filing Date: July 18, 2003	Group Art Unit: 1645

U.S. PATENT DOCUMENTS						
EXAMINER INITIALS	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 01/23414	04/05/2001	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Fuhlbrigge, Robert C. et al., "Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells", Nature, 30 October 1997, Vol. 389, pages 978-981.
		Khan, Naeem et al., "Comparative Analysis of CD8+ T Cell Responses against Human Cytomegalovirus Proteins pp65 and Immediate Early 1 Shows Similarities in Precursor Frequency, Oligoclonality, and Phenotype", The Journal of Infectious Diseases, March 2002, Vol. 185, pages 1025-1034.
		Marshall, Natalie A. et al., "Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation", Immunology, 15 October 2000, Blood, Vol. 96, No. 8, pages 2814-2821.
		Pober, Jordan S. et al., "Human Endothelial Cell Presentation of Antigen and the Homing of Memory/Effector T Cells to Skin", Annals New York Academy of Sciences, 2001, Vol. 941, pages 12-25.
		Stanberry, Lawrence R. et al., "Prospects for Control of Herpes Simplex Virus Disease through Immunization", Clinical Infectious Diseases, March 2000, Vol. 30, pages 549-566.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	